Author

Bruno Sangro

Instituto de Salud Carlos IIIORCID 0000-0002-4177-6417Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 2 Organism:mouse· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Research Focus:cell-cell communication· 1 Approach:deep learning· 1 Research Focus:differential expression· 1 Approach:experimental assay· 1

Frequent Co-Authors

Eva Santa MaríaiD· 2 shared Josepmaria ArgemíiD· 2 shared Pablo SarobeiD· 2 shared Agavni MesropianiD· 1 shared Albert Gris‐OliveriD· 1 shared Alexander FinnemoreiD· 1 shared Alexis I. CocozakiiD· 1 shared Amaia ÚriziD· 1 shared

Activity by Year

2026-2026 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 35 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Eva Santa MaríaORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cancer BiologybioRxivPreprintMay 16, 2026

ATF4 programs proline-dependent immune evasion in β-Catenin-driven hepatocellular carcinoma

Stefany Infante, Eva Santa María, Alexander Finnemore…·Josepmaria Argemí

This study identifies ATF4 as a key driver of immune evasion in β-catenin-driven hepatocellular carcinoma by programming a proline-dependent metabolic axis that suppresses anti-tumor immunity.

DOI 10.64898/2026.05.12.724215

humanmouse

𝕏 PostBluesky

Pharmacology & ToxicologyCell Reports MedicinePeer-reviewedMar 31, 2026

Histone methyl-transferase G9a inhibition boosts the efficacy of immune checkpoint inhibitors in experimental hepatocellular carcinoma

Elena Adán-Villaescusa, Borja Castelló-Uribe, Iker Uriarte…·Maite G Fernandez-Barrena

This study shows that inhibiting G9a enhances the effectiveness of immune checkpoint inhibitors in hepatocellular carcinoma by improving tumor immunogenicity and T cell infiltration.

3 citationstop 2%

mousebulk RNA-seq

𝕏 PostBluesky